A genotype decides whether a patient can take the oral therapy at all. Sizing that ignores the amenable-mutation split is sizing the wrong population.
Oral chaperone therapy is available only to patients whose mutation is amenable to it, which splits the treated population in two before any commercial question is asked. Every Fabry model has to carry that split explicitly, because the two segments have different treatment options, different switch dynamics and different lifetime costs.
Two switch flows drive share and have to be modelled separately. The first moves newly treated amenable-mutation patients from enzyme replacement onto oral therapy. The second moves established patients between agents for reasons that have more to do with tolerability, infusion burden and clinic capacity than with efficacy. Combining them into a single conversion rate produces a forecast that cannot be defended in review.
The larger opportunity, though, is not switching at all. Later-onset patients and female patients are systematically under-identified, and family cascade screening from a confirmed index case finds them at a rate no promotional programme matches. In a disease where the identification funnel rather than share of a fixed pool is the strategy, investment in cascade screening returns more than investment in competitive displacement.
Enzyme replacement economics are extreme and have persisted, with no biosimilar entry after two decades on market, so the value case has to be modelled per genotype segment across a treatment lifetime.
AXLRx Fabry reports size the diagnosed base and the amenable-mutation split across the US, UK and Gulf, and model both switch flows independently.
Pegunigalsidase now challenges Fabrazyme's two-decade lead in US Fabry disease. Two IV enzyme replacement therapies meet an oral chaperone only ~35–50% of patients can take.
Fabry disease splits into classic childhood-onset and a largely undiagnosed later-onset cardiac form. An X-linked organ timeline and the ~35–50% amenable-mutation gate decide who is treatable.
A genetic test gates oral migalastat, and IV enzyme replacement sits in Part B. Fabrazyme has no US biosimilar, and the IRA's orphan-drug exclusion shields it from Medicare price negotiation.
GCC is a two-ERT Fabry market, with agalsidase alfa via the EMA pathway alongside agalsidase beta. Migalastat's oral advantage, covering 35-50% of patients, is bottlenecked by the single GCC lab that can run the amenable-mutation assay.
The £144M NHS Fabry market is the largest in Europe, and already has two established agents. An ADA-positive or female-heterozygote niche, not general ERT improvement, is the only viable UK entry point.
Pegunigalsidase's suboptimal-responder recommendation (TA915) reshapes NHS-commissioned Fabry therapy. It sets oral migalastat against IV enzyme replacement across the UK treated population.
700-900 NHS-diagnosed Fabry patients split cleanly by therapy. Roughly 600 are on enzyme replacement and about 200, or 25%, on oral migalastat, with free NHS cascade testing adding 3-4 diagnosed relatives per index case.
NPHC has a 72%-cost-reduction incentive to switch amenable-mutation Fabry patients from ERT to migalastat. A single HEK293 assay lab in the entire GCC is the only thing standing in the way.
Both approved Fabry ERTs are already NPHC-covered in the GCC, so the constraint is finding an unaddressed niche. That means the 30-50 patient ADA-positive cohort, or the HEK-assay bottleneck that locks non-KFSH&RC patients out of oral therapy.
Migalastat's HST4 recommendation in 2016 was the first oral mutation-specific rare disease therapy NICE approved. Agalsidase beta was never formally appraised at all. Together they underpin an estimated £144M NHS Fabry programme, with a £70-130K/patient/year switch incentive still unrealised at scale.
Agalsidase beta runs an estimated £150-250K per patient per year against migalastat's £80-120K. NICE has quantified that £70-130K annual switch saving but the NHS has not captured it at scale, and pegunigalsidase's TA915 commercial arrangement now sets a third price point.
NPHC pays roughly SAR 1.2-2.4M per patient per year for enzyme replacement against SAR 400-600K for migalastat. That 72% differential gives NPHC a direct incentive to switch eligible patients, capped almost entirely by a single-laboratory diagnostic bottleneck rather than by price.
The ADA-positive suboptimal-agalsidase-responder niche (200–400 US patients) is Fabry's only clean pre-launch opening.
Roughly 5,000-10,000 diagnosed US Fabry patients split first by GLA amenability, with 35-50% oral-eligible. ADA status narrows that to a precise 200-400 patient addressable niche, which a Fabrazyme-anchored $250-350K WAC makes commercially calculable.
5,000-10,000 diagnosed US classic Fabry patients face a 35-50% amenable-mutation gate to oral therapy. The treated population is still 60-65% on enzyme replacement. This funnel starts at diagnosis because no defensible undiagnosed estimate exists yet.
GCC male Fabry prevalence runs 1:20,000-30,000, elevated by founder mutations. Only 200-300 patients are diagnosed against a true burden estimated 3-5 times higher, and female diagnosis lags at under half the male rate.
KFSH&RC runs the only HEK293 amenable-mutation assay in the GCC. Its formulary committee recommendation drives NPHC coverage decisions for every Fabry disease treatment. That kind of single-institution gatekeeping is exactly the concentration this workbook sizes before any individual name enters it.
Arabian Peninsula founder mutations, the female diagnosis gap, and the HEK assay bottleneck limiting oral chaperone therapy access across the GCC.
Fabrazyme's orphan-drug exclusion under the IRA shields it from Medicare price negotiation entirely. No rebate or net-price figure is disclosed anywhere in the primary record for any Fabry therapy. The orphan exclusion, not a discount ladder, is what a Fabry pricing strategy has to be built around.
An estimated 800-patient UK Fabry cohort has both NHS-commissioned ERT and NICE HST4-recommended oral chaperone therapy. The NHS lysosomal-storage-disorder specialist network and UK Fabry Outcome Survey longitudinal data track it.
700-900 diagnosed UK Fabry patients split roughly 600 on ERT to 200 on oral therapy. Two niches sit inside that: 50-80 ADA-positive suboptimal responders and 80-120 undertreated symptomatic female heterozygotes, against a £144M NHS spend anchor.
200-300 diagnosed GCC Fabry patients sit against a true prevalence estimated 3-5 times higher. A single regional laboratory gates the amenable-mutation test, and female heterozygotes are diagnosed at under half the male rate.
UK Fabry disease is commissioned through three different NICE and NHS routes at once. No formal technology appraisal for either enzyme replacement therapy, a Highly Specialised Technologies recommendation (HST4, 2016) for migalastat, and a standard appraisal (TA915, 2023) for pegunigalsidase alfa. A new entrant inherits no single reusable comparator or price benchmark.
Royal Free London's National Fabry Service was NICE's appointed clinical expert twice over. It advised on both migalastat's HST4 and pegunigalsidase alfa's TA915, across a network of five named NHS lysosomal storage disorder centres. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it.
Fabry disease is an X-linked deficiency of alpha-galactosidase A caused by GLA mutations, and it presents in two faces. Classic multi-organ disease affects roughly 5,000 to 10,000 diagnosed US patients, about 1 in 40,000 males, from childhood. A later-onset, cardiac-predominant form emerges in the fifth or sixth decade and stays largely undiagnosed, so true prevalence runs higher than the recognised population. Because inheritance is X-linked, female heterozygotes also develop significant multi-organ disease, typically about a decade later than males. The organ timeline runs renal to cardiac to cerebrovascular, with cardiac disease now the leading cause of death.
Diagnosis starts with a plasma or dried-blood-spot alpha-galactosidase A enzyme assay, followed by GLA genetic sequencing to confirm the mutation and to detect female heterozygotes whom the enzyme assay can miss. A validated HEK293 cell-based amenability assay then determines whether a patient's specific GLA mutation qualifies for the oral chaperone migalastat. Family cascade screening after an index diagnosis is the primary driver of new patients entering the treated funnel, yielding several additional diagnosed relatives per index case. Later-onset and female patients remain systematically under-identified, so the diagnosed population sits well below the true burden.
Three therapies span two mechanisms. Two are intravenous enzyme replacement therapies: agalsidase beta (Fabrazyme, Sanofi Genzyme, approved 2003) and pegunigalsidase alfa (Elfabrio, Chiesi and Protalix, approved 2023), which was non-inferior to agalsidase beta on eGFR slope in the BALANCE trial. The third is the oral pharmacological chaperone migalastat (Galafold, Amicus Therapeutics, approved 2018), which stabilises amenable mutant enzyme and is indicated only for the roughly 35 to 50% of patients with an amenable GLA mutation confirmed by the HEK293 assay. In the GCC, a second ERT, agalsidase alfa (Replagal, Takeda), is also registered.
The method is genotype-amenability segmentation, not treated-patient share. Start from the diagnosed base, an estimated 5,000 to 10,000 US classic patients, then apply amenable-mutation status as the first sizing gate. A validated HEK293 assay determines whether a patient's specific GLA mutation is amenable to oral migalastat, splitting the population into a 35 to 50% oral-eligible segment and an ERT-only remainder. That single genotype gate reshapes the addressable market: the oral-eligible segment is contestable by migalastat and any future chaperone, while the ERT-only segment stays anchored to agalsidase beta and pegunigalsidase alfa. A second gate then isolates the roughly 200 to 400 ADA-positive inadequate responders inside the ERT population. Segmentation by genotype defines where each agent can actually compete.
In Fabry the identification funnel, not share of a fixed pool, is the strategy, because later-onset and female patients are systematically under-identified. The core lever is family cascade screening: after each index diagnosis, GLA testing of relatives yields several additional diagnosed cases per index patient. In the UK, NHS Genomic Medicine Service cascade testing produces roughly three to four new diagnoses per index case and drives most new entrants into the treated funnel. In the GCC, founder-mutation clusters documented at KFSH&RC yield three to five affected relatives per family, yet female heterozygotes are diagnosed at under half the male rate despite carrying an estimated two to three times the male disease burden. A model that sizes cascade yield and the female diagnosis gap captures growth an incidence-only view misses entirely.
Two distinct switch flows drive Fabry share, and modelling them separately is what makes a forecast defensible. The first is ERT-to-oral: among newly treated amenable-mutation patients, an estimated 50 to 60% now start on oral migalastat, up from 40 to 50% choosing ERT in 2020, though agalsidase beta still holds 60 to 65% of the treated base after two decades of incumbency. The second is ERT-to-ERT: pegunigalsidase alfa, non-inferior to agalsidase beta on eGFR slope in BALANCE, is positioned at suboptimal responders rather than the naive base. Roughly 30 to 40% of male classic patients develop high-titre anti-drug antibodies within three to five years, defining an ADA-positive switch pool. A single net-share number hides all three of these flows.
ERT lifetime economics are extreme, so the value case must model them per genotype segment. Agalsidase beta carries an annual WAC near $250,000 to $350,000 with no US biosimilar after two decades on market, and it is exempt from IRA Medicare price negotiation under the sole-orphan-indication exclusion. Because Fabry is lifelong, that cost compounds across decades of biweekly infusion, while oral migalastat removes infusion-chair and administration burden for the amenable segment. In the UK, switching an eligible patient from ERT to oral saves an estimated 70,000 to 130,000 pounds per year, a saving already quantified but not captured at scale. Payer economics differ entirely between the amenable and ERT-only populations, so a single blended cost figure understates the oral opportunity and the ERT lock-in.
Each answer above is drawn from AXLRx Fabry disease briefs built across the US, UK, and GCC. Disease Landscape and Patient Flow Models size the diagnosed base and the amenable-mutation split; Market Sizing gates the ADA-positive and female-heterozygote niches; Competitive Intelligence maps agalsidase beta, pegunigalsidase alfa, and migalastat; Payer, HTA, and Pricing work covers Part B versus Part D routing, switch economics, and the single-laboratory diagnostic bottleneck that gates access in the GCC; KOL Mapping tiers the referral centres that control it. Every figure is built from primary regulatory and payer sources and delivered as a verified PDF, an editable Excel model, and a readout deck. The through-line is consistent: in Fabry, the identification and segmentation funnel is the strategy, not share of a fixed pool.